Detailed price information for Arbutus Biopharma Corp (ABUS-Q) from The Globe and Mail including charting and trades.

Cancer vaccines in development rely on mRNA technology under attack by RFK Jr. “I am concerned that this could bleed over," ...

One vaccine expert called the move, which cancels some $500 million in messenger RNA research contracts, a “giant step ...

Kennedy’s newest decision comes amid a string of vaccine pullbacks at the health department in recent months. In May, he said ...

BioNTech also laid off 63 employees in June in conjunction with the discontinuation of its cell therapy manufacturing ...

Many viruses circulate seasonally, picking up as the weather cools in the fall and winter. So it’s true that fewer people get ...

BioNTech SE BNTX -0.15% Get Free Report reported a narrower loss for the second quarter on Monday. The company posted a second-quarter per-share loss of $1.82 (1.60 euros) on Monday, versus a loss of ...

As part of a "strategic alignment" of its pipeline, BioNTech is laying off 90 workers in R&D and corporate roles across two sites in Maryland and Massachusetts, a spokesperson told Fierce. | As part ...

Why it matters: In addition to ongoing clinical trial progress for BNT327, BioNTech was active on the business development ...

Live Updates Live Coverage Has Ended Monday Wrap-up 4:26 pm The Vanguard S&P 500 ETF closed at 580.14 Monday, up 1.5% — almost an exact mirror of Friday’s 1.6% decline. ViaSat Goes to the Moon 1:21 pm ...

CAMBRIDGE, MA / ACCESS Newswire / August 1, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the UK Court of Appeal ...

BioNTech SE BNTX +3.21% Get Free Report reported a second-quarter per-share loss of $1.82 (1.60 euros) on Monday, up from a loss of 3.36 euros reported a year ago, compared to beating the consensus ...